Current Perspectives on the Attainment of Lipid Modification Goals Relating to the Use of Statins and Ezetimibe for the Prevention of Cardiovascular Disease in the United Kingdom

References

• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi:10.1093/eurheartj/ehx144
   PubMed Web of Science ®Google Scholar
• Alkhalil M. Effects of intensive lipid-lowering therapy on mortality after coronary bypass surgery: a meta-analysis of 7 randomised trials. Atherosclerosis. 2020;293:75–78. doi:10.1016/j.atherosclerosis.2019.12.006
   PubMed Web of Science ®Google Scholar
• Armitage J, Baigent C, Barnes E, Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–415. doi:10.1016/S0140-6736(18)31942-1
   PubMed Web of Science ®Google Scholar
• Scottish Intercollegiate Guidelines Network (SIGN). SIGN 149. Risk estimation and the prevention of cardiovascular disease. 2017. Available from: https://www.sign.ac.uk/assets/sign149.pdf. Accessed April 29, 2021.
   Google Scholar
• Giugliano RP, Pedersen TR, Park J-G, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962–1971. doi:10.1016/S0140-6736(17)32290-0
   PubMed Web of Science ®Google Scholar
• De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135–146. doi:10.1016/j.atherosclerosis.2019.03.014
   PubMed Web of Science ®Google Scholar
• Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart. 2019;105(13):975–981. doi:10.1136/heartjnl-2018-314253
   PubMed Web of Science ®Google Scholar
• Danese MD, Gleeson M, Kutikova L, et al. Management of lipid-lowering therapy in patients with cardiovascular events in the UK: a retrospective cohort study. BMJ Open. 2017;7(5):e013851. doi:10.1136/bmjopen-2016-013851
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Cardiovascular disease: risk assessment and reduction, including lipid modification. CG181. Available from: www.nice.org.uk/guidance/cg181. Accessed April 29, 2021.
   Google Scholar
• Vallejo-Vaz AJ, Robertson M, Catapano AL, et al. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. Circulation. 2017;136(20):1878–1891. doi:10.1161/CIRCULATIONAHA.117.027966
   PubMed Web of Science ®Google Scholar
• Karlson BW, Palmer MK, Nicholls SJ, Barter PJ, Lundman P. Effects of age, gender and statin dose on lipid levels: results from the VOYAGER meta-analysis database. Atherosclerosis. 2017;265:54–59. doi:10.1016/j.atherosclerosis.2017.08.014
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2017;70(2):115. doi:10.1016/j.rec.2017.01.002
   Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskThe task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111–188. doi:10.1093/eurheartj/ehz455
   PubMed Web of Science ®Google Scholar
• Overview. Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. Guidance. NICE. Available from: https://www.nice.org.uk/guidance/ta385. Accessed April 29, 2021.
   Google Scholar
• Familial hypercholesterolaemia: identification and management: NICE guidance [CG71]. Available from: https://www.nice.org.uk/guidance/cg71/chapter/Recommendations. Accessed December 4, 2020.
   Google Scholar
• Saratzis A, Jaspers NEM, Gwilym B, et al. Observational study of the medical management of patients with peripheral artery disease. Br J Surg. 2019;106(9):1168–1177. doi:10.1002/bjs.11214
   PubMed Web of Science ®Google Scholar
• Nordstrom B, Collins J, Donaldson R, Tockhorn A, Zhu Y, Zhao Z. Treatment patterns and lipid levels among patients with high-risk atherosclerotic CVD in the UK. Br J Cardiol. 2015;22:147–154. doi:10.5837/bjc.2015.034
   Google Scholar
• Finnikin S, Ryan R, Marshall T. Statin initiations and QRISK2 scoring in UK general practice: a THIN database study. Br J Gen Pract. 2017;67(665):e881–e887. doi:10.3399/bjgp17X693485
   PubMed Web of Science ®Google Scholar
• Matthews A, Herrett E, Gasparrini A, et al. Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data. BMJ. 2016;353:i3283. doi:10.1136/bmj.i3283
   PubMed Web of Science ®Google Scholar
• Ferrieres J, De Ferrari GM, Hermans MP, et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: results from DYSIS II Europe. Eur J Prev Cardiol. 2018;25(18):1966–1976. doi:10.1177/2047487318806359
   PubMed Web of Science ®Google Scholar
• Williams B, Masi S, Wolf J, Schmieder RE. Facing the challenge of lowering blood pressure and cholesterol in the same patient: report of a symposium at the European Society of hypertension. Cardiol Ther. 2020;9(1):19–34. doi:10.1007/s40119-019-00159-1
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP. Statin intolerance: some practical hints. Cardiol Clin. 2018;36(2):225–231. doi:10.1016/j.ccl.2017.12.004
   PubMed Web of Science ®Google Scholar
• Preiss D, Neely D. Biochemistry laboratories should routinely report non-HDL-cholesterol. Ann Clin Biochem. 2015;52(6):629–631. doi:10.1177/0004563215594818
   PubMed Web of Science ®Google Scholar
• Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clin Res Cardiol. 2017;106(4):237–248. doi:10.1007/s00392-016-1069-7
   PubMed Web of Science ®Google Scholar
• Toth PP, Banach M. Statins: then and now. Methodist DeBakey Cardiovasc J. 2019;15(1):23–31. doi:10.14797/mdcj-15-1-23
   PubMedGoogle Scholar
• Elamin AFM, Grafton-Clarke C, Wen Chen K, et al. Potential use of PCSK9 inhibitors as a secondary preventative measure for cardiovascular disease following acute coronary syndrome: a UK real-world study. Postgrad Med J. 2019;95(1120):61–66. doi:10.1136/postgradmedj-2018-136171
   PubMed Web of Science ®Google Scholar
• Overview. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Guidance. NICE. Available from: https://www.nice.org.uk/guidance/ta394. Accessed April 29, 2021.
   Google Scholar
• Overview. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Guidance. NICE. Available from: https://www.nice.org.uk/guidance/ta393. Accessed April 29, 2021.
   Google Scholar
• National Institute for Health and Care Excellence. British National Formulary: indications, dose, contra-indications, side-effects, interactions, cautions, warnings and other safety information for BEMPEDOIC ACID. Available from: https://bnf.nice.org.uk/drug/bempedoic-acid.html. Accessed January 21, 2021.
   Google Scholar
• European Medicines Agency. Leqvio. European Medicines Agency. October 13, 2020. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio. Accessed January 21, 2021.
   Google Scholar
• Cohen JD, Cziraky MJ, Jacobson TA, Maki KC, Karalis DG. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: results of a healthcare provider survey conducted by the National Lipid Association. J Clin Lipidol. 2017;11(4):891–900. doi:10.1016/j.jacl.2017.04.120
   PubMed Web of Science ®Google Scholar
• Royal Brompton & Harefield NHS Foundation Trust. New opportunities for the treatment of hyperlipidaemia: initiation of PCSK9 monoclonal antibodies utilising a multi-disciplinary approach. NICE. Available from: https://www.nice.org.uk/sharedlearning/new-opportunities-for-the-treatment-of-hyperlipidaemia-initiation-of-pcsk9-monoclonal-antibodies-utilising-a-multi-disciplinary-approach. Accessed April 29, 2021.
   Google Scholar
• Leeds Teaching Hospitals NHS Trust. Innovative medicines optimisation clinic for PCSK9 inhibitors & statin intolerance. Available from: https://www.nice.org.uk/sharedlearning/innovative-medicines-optimisation-clinic-for-pcsk9-inhibitors-statin-intolerance. Accessed April 29, 2021.
   Google Scholar
• Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med. 2020;383(22):2182–2184. doi:10.1056/NEJMc2031173
   PubMed Web of Science ®Google Scholar
• Aubiniere-Robb L, Dickerson JE, Brady AJB. Lipid testing and treatment after acute myocardial infarction: no flags for the flagship. Br J Cardiol. 2019;26:141–144. doi:10.5837/bjc.2019.041
   Google Scholar
• Danese MD, Pemberton-Ross P, Catterick D, Villa G. Estimation of the increased risk associated with recurrent events or polyvascular atherosclerotic cardiovascular disease in the United Kingdom. Eur J Prev Cardiol. 2020;1–10. doi:10.1177/2047487319899212
   Web of Science ®Google Scholar
• Drexel H, Coats AJS, Spoletini I, et al. ESC position paper on statins adherence and implementation of new lipid-lowering medications: barriers to be overcome. Eur Heart J Cardiovasc Pharmacother. 2019. doi:10.1093/ehjcvp/pvz079
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complaints. J Am Coll Cardiol. 2017;70(10):1290–1301. doi:10.1016/j.jacc.2017.07.752
   PubMed Web of Science ®Google Scholar
• Connolly SB, Kotseva K, Jennings C, et al. Outcomes of an integrated community-based nurse-led cardiovascular disease prevention programme. Heart. 2017;103(11):840–847. doi:10.1136/heartjnl-2016-310477
   PubMed Web of Science ®Google Scholar
• Waters DD, Boekholdt SM. An evidence-based guide to cholesterol-lowering guidelines. Can J Cardiol. 2017;33(3):343–349. doi:10.1016/j.cjca.2016.10.019
   PubMed Web of Science ®Google Scholar
• Graham I, Shear C, De Graeff P, et al. New strategies for the development of lipid-lowering therapies to reduce cardiovascular risk. Eur Heart J Cardiovasc Pharmacother. 2018;4(2):119–127. doi:10.1093/ehjcvp/pvx031
   PubMed Web of Science ®Google Scholar
• Soran H, Kwok S, Adam S, Ho JH, Durrington PN. Evidence for more intensive cholesterol lowering. Curr Opin Lipidol. 2017;28(4):291–299. doi:10.1097/MOL.0000000000000433
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Cardiovascular disease prevention overview. Available from: https://pathways.nice.org.uk/pathways/cardiovascular-disease-prevention. Accessed April 29, 2021.
   Google Scholar
• Patient decision aid. Cardiovascular disease: risk assessment and reduction, including lipid modification. Guidance. NICE. Available from: https://www.nice.org.uk/guidance/cg181/resources/patient-decision-aid-188102. Accessed April 29, 2021.
   Google Scholar